Overview

An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

Status:
Completed

Trial end date:
2019-01-18

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of vedolizumab intravenous (IV) treatment compared to adalimumab subcutaneous (SC) treatment over a 52-week treatment period.

Phase:

Phase 3

Details

Lead Sponsor:

Takeda

Treatments:

Adalimumab
Vedolizumab